Exhibit 3.3 EXCLUSIVE LICENSE AGREEMENT THIS NON-EXCLUSIVE LICENSE AGREEMENT ("Agreement") is made and effective as of May 3, 2008 (the "Effective Date") by and between Microbial Technologies Limited, a company registered in the United Kingdom with an...Exclusive License Agreement • January 12th, 2009 • Organic Sales & Marketing Inc • Wholesale-groceries & related products
India inks biosimilar agreement with Japan, KoreaExclusive License Agreement • August 1st, 2021
EXCLUSIVE LICENSE AGREEMENT WITH EQUITYExclusive License Agreement • September 1st, 2022 • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and (“*****”), a corporation having a principal place of business at , is effective on the day of , 20 (“Effective Date”).
EXCLUSIVE LICENSE AGREEMENT FOR [ TITLE ]*Exclusive License Agreement • March 13th, 2024 • California
This exclusive license agreement (“AGREEMENT”) is effective on [DATE] (“Effective Date”), and is by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, whose legal address is 1111 Franklin Street, 12th Floor, Oakland, California 94607- 5200, acting through its Office of Technology Licensing, at the University of California, Berkeley, 2150 Shattuck Avenue, Suite 408, Berkeley, CA 94704-1362 ("REGENTS") and [LICENSEE name], a [State of incorporation] corporation having a principal place of business at [LICENSEE address] ("LICENSEE"). The parties agree as follows:
1. BACKGROUNDExclusive License Agreement • November 8th, 2005 • Molecular Insight Pharmaceuticals, Inc. • District of Columbia
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • January 10th, 2008 • Rxi Pharmaceuticals Corp • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of April 15, 2003 (the “Effective Date”), is between the University of Massachusetts Medical School (“Medical School”), a public institution of higher education of the Commonwealth of Massachusetts having an address of 55 Lake Avenue North, Worcester, MA 01655, and CytRx Corporation (“Company”), a Delaware corporation having an address of 11726 San Vicente Blvd., Suite 650, Los Angeles, CA 90049.
EX-10 21 filename21.htm CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION....Exclusive License Agreement • May 5th, 2020 • Pennsylvania
This Agreement is made and entered into as of the 30th day of September, 2013 (“Effective Date”), by and between the University of Pittsburgh – Of the Commonwealth System of Higher Education, a non-profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania, with an office at 200 Gardner Steel Conference Center, Thackeray and O’Hara Streets, Pittsburgh, Pennsylvania 15260 (“University”), and EXAGEN DIAGNOSTICS, INC., a corporation organized and existing under the laws of Delaware, having an office at 800 Bradbury Drive SE Suite 108, Albuquerque, NM 87106 (“Licensee”).
EXCLUSIVE license agreement Between CLENERGEN CORPORATION And BIOPOWER CORPORATION November 30, 2010Exclusive License Agreement • June 10th, 2011 • Biopower Operations Corp • Agricultural production-crops • Florida
This Agreement (the "Agreement"), dated November 30, 2010 (the Effective Date) is entered into by and between Clenergen Corporation, a Nevada corporation and public company (Licensor) and BioPower Corporation, a Florida corporation (Licensee).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • January 10th, 2008 • Rxi Pharmaceuticals Corp • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of January 10, 2007 (the “Effective Date”), is between the University of Massachusetts (“University”), a public institution of higher education of the Commonwealth of Massachusetts as represented by its Worcester campus, and RXi Pharmaceuticals Corporation (“Company”), a Delaware corporation.
EXCLUSIVE LICENSE AGREEMENT by and between AMGEN INC. and SANTA MARIA BIOSCIENCES, INC. Dated as of September 7, 2012Exclusive License Agreement • July 10th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of September 7, 2012 (the “Signing Date”) by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”), and SANTA MARIA BIOSCIENCES, INC., a Delaware corporation (“Company”). Company and Amgen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
EXCLUSIVE LICENSE AGREEMENT between Heart Test Laboratories, Inc. and Icahn School of Medicine at Mount SinaiExclusive License Agreement • September 21st, 2023 • Heart Test Laboratories, Inc. • Orthopedic, prosthetic & surgical appliances & supplies • New York
This Exclusive License Agreement (this “Agreement”) is by and between Icahn School of Medicine at Mount Sinai, a New York not-for-profit education corporation, with a principal place of business at One Gustave L. Levy Place, New York, NY 10029 (“Mount Sinai”) and Heart Test Laboratories, Inc. d/b/a HeartSciences a Texas corporation, with a principal place of business at 550 Reserve Street, Suite 360, Southlake, TX 76092 (referred to herein as (“Licensee”). This Agreement shall become effective upon the Closing (the “Effective Date”), which shall be deemed the Closing Date. Mount Sinai and Licensee are each referred to herein as a “Party” and collectively as the “Parties.” Terms not defined herein shall have the meaning ascribed to them in the Securities Purchase Agreement between the Parties, executed contemporaneously herewith (the “SPA”) and annexed hereto as Exhibit A.
EX-10.10 2 filename2.htm ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. EXCLUSIVE LICENSE AGREEMENT This Exclusive License...Exclusive License Agreement • May 5th, 2020
WHEREAS, IDC is the University of Victoria’s (UVic’s) corporation for commercialization of intellectual property and discoveries; and
EXHIBIT 10.13 EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • July 16th, 1999 • Scientific Learning Corp • Services-educational services • California
AMENDMENT NO. 1 TO THE EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This AMENDMENT NO. 1 TO THE EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), dated as of October 22, 2012 (the “Amendment Effective Date”), is made by and between AMGEN INC., a Delaware corporation having an address of One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”), and NINA BIOTHERAPEUTICS, INC., a Delaware corporation (“Licensee”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • November 8th, 2011 • Newlink Genetics Corp • Pharmaceutical preparations • Pennsylvania
THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made and entered into by and between LANKENAU INSTITUTE FOR MEDICAL RESEARCH (“LIMR”) and NEWLINK GENETICS CORPORATION (“NewLink”) for the licensing of certain intellectual property rights to NewLink, effective on this day of October, 2007 (the “Effective Date”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • June 14th, 2021 • Alpha Healthcare Acquisition Corp. • Biological products, (no disgnostic substances) • Connecticut
THIS AGREEMENT (this “Agreement”) by and between YALE UNIVERSITY, a corporation organized and existing under and by virtue of a charter granted by the general assembly of the Colony and State of Connecticut and located in New Haven, Connecticut (“YALE”), and Humacyte, Inc. a corporation organized and existing under the laws of the State of Delaware and with principal offices located at 2525 E. NC Highway 54 in Durham, NC (“LICENSEE”) is effective as of August 25, 2019 (“EFFECTIVE DATE”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • September 28th, 2021 • Kansas
This license agreement (“Agreement”) is entered into this _ day of , 20 (Effective Date) by and between the University of Kansas, a public research university having its principal place of business at 1450 Jayhawk Blvd., Lawrence, KS 66045, hereinafter referred to as “KU” or “Licensor,” and [Company Name], having its principal place of business at _, hereinafter referred to as “Licensee.”
EXCLUSIVE LICENSE AMENDING AGREEMENTExclusive License Agreement • February 15th, 2013 • Sophiris Bio Inc. • Pharmaceutical preparations
UNIVERSITY OF VICTORIA INNOVATION AND DEVELOPMENT CORPORATION, a corporation owned by the University of Victoria, having its principal office at R-Hut, McKenzie Avenue, Victoria, British Columbia, Canada, V8W 3W2
Exclusive License Agreement for Selected Applications of Coated Nanocrystalline ParticlesExclusive License Agreement • February 24th, 2000 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
EXCLUSIVE LICENSE AGREEMENT *Exclusive License Agreement • September 29th, 2022 • California
This exclusive license agreement (“AGREEMENT”) is effective [ ] (“Effective Date”), by and between REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, whose legal address is 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through its Office of Technology Licensing, at the University of California, Berkeley, 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94720-1366 ("REGENTS") and [ ], a [ ] corporation having a principal place of business at [ ] ("LICENSEE"). The parties agree as follows:
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 27th, 2022 • Rhode Island
This Exclusive License Agreement (this “Agreement”) is entered into as of January 25, 2021 , 2021 (the “Effective Date”), by and between Elkurt Inc. a Rhode Island corporation, with an address at 297 President Ave, Providence RI 02906 (“Elkurt”) and Ocean Biomedical Inc, a Delaware corporation with an address at 19W060 Avenue LaTours, Oak Brook, IL 60523 (“Licensee”).
EXHIBIT 10.7Exclusive License Agreement • April 20th, 2006 • Quatrx Pharmaceuticals Co • Pharmaceutical preparations • Michigan
EX-10.15 12 d503245dex1015.htm EX-10.15 Confidential Treatment Requested by Homology Medicines, Inc. EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 5th, 2020 • California
THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made and entered into as of the 28th day of April, 2016 (the “Effective Date”) by and between Homology Medicines, Inc., a Delaware corporation with a principal place of business at 44 Hartwell Avenue, Suite 102, Lexington, Massachusetts 02421 (“Licensee”) and City of Hope, a California nonprofit public benefit corporation located at 1500 East Duarte Road, Duarte, California 91010 (“City of Hope” or “COH”). Licensee and COH are each sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
UO FASTER FLIGHT STARTUP LICENSE AGREEMENT BETWEENExclusive License Agreement • May 28th, 2022 • Oregon
This Exclusive License Agreement (this “Agreement”), is dated and effective as of the date of last signature (the “Effective Date”), and is made and entered into between the University of Oregon, a public institution of higher education in the state of Oregon, (“University”), and , a (“Company”).
Exclusive License AgreementExclusive License Agreement • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations • California
This Exclusive License Agreement (“Agreement”) is entered into as of this 2nd day of June 2021 (“Effective Date”) by and between Cedars-Sinai Medical Center, a California nonprofit public benefit corporation (“CSMC”), with offices at 8700 Beverly Boulevard, Los Angeles, California 90048-1865, and Enviro Therapeutics, Inc., (“Licensee”), with offices at 2355 Westwood Blvd., #139, Los Angeles, CA 90069.
EXHIBIT 10.5 EXCLUSIVE LICENSE AGREEMENT THIS AGREEMENT made and entered into as of March 22, 2006 ("Effective Date"), by and between NANODYNAMICS, INC., a Delaware corporation, with offices at 901 Fuhrmann Boulevard, Buffalo, NY 14203 ("NANO") and...Exclusive License Agreement • June 15th, 2007 • NanoDynamics, Inc. • Services-commercial physical & biological research
CAROLINA EXPRESS EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • October 22nd, 2021 • North Carolina
day of , 20_ (the “Effective Date”) between The University of North Carolina at Chapel Hill having an address at 109 Church St, Chapel Hill, NC, 27516 (“University”) and
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 9th, 2017 • uniQure N.V. • Pharmaceutical preparations • New York
THIS Exclusive License Agreement (“Agreement”), effective as of 07 July 2008 (“Effective Date”), is entered into by and between St. Jude Children’s Research Hospital, Inc., a Tennessee not-for-profit corporation located at 262 Danny Thomas Place, Memphis, Tennessee 38105 (“ST. JUDE”) and Amsterdam Molecular Therapeutics B.V., a closed limited liability company organized and existing under the laws of the Netherlands, with registered offices at Meibergdreef 61, 1105 BA Amsterdam, the Netherlands, (each a “Party” and together the “Parties”).
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 1st, 2019 • Exagen Inc. • Services-medical laboratories • New Mexico
This Agreement (“Agreement”) is made and entered into as of the 5th day of September, 2011 (“EFFECTIVE DATE”), by and between Thierry DERVIEUX an individual and his company DeNovo, a California limited liability corporation, located at, 240 Coral Rose Irvine, CA 92603 (“DERVIEUX”), and EXAGEN DIAGNOSTICS, INC., a corporation organized and existing under the laws of Delaware, having an office at 801 University Blvd. SE Suite 103 Albuquerque, NM 87106 (“EXAGEN”).
EXHIBIT 10.4 THIS LICENSE AGREEMENT NOT VALID UNTIL EXECUTION COPIES HAVE BEEN SIGNED BY ALL PARTIES. EXCLUSIVE LICENSE AGREEMENT THIS AGREEMENT (the "Agreement") by and between YALE UNIVERSITY, a corporation organized and existing under and by virtue...Exclusive License Agreement • August 20th, 2004 • Email Real Estate Com Inc • Services-business services, nec • Connecticut
EX-10.1 4 d197669dex101.htm AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT Execution Version THE GENERAL HOSPITAL CORPORATION AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT MGH Amended and Restated Agreement No: MGH Case No.: 1814Exclusive License Agreement • May 5th, 2020 • Massachusetts
This Amended and Restated License Agreement (“AGREEMENT”), is made as of September 21, 2011, between Zeltiq Aesthetics, Inc. a Delaware corporation, having a principal place of business at 4698 Willow Road, Pleasanton, CA 94588 (“COMPANY”), formerly known as Juniper Medical, Inc., a Delaware corporation (“JUNIPER”), and The General Hospital Corporation, a not-for-profit corporation d/b/a Massachusetts General Hospital, having a place of business at 55 Fruit Street, Boston, MA 02114 (“HOSPITAL”). This AGREEMENT replaces the Exclusive License Agreement, MGH Agreement No. 2004A18936, dated and effective May 17, 2005, (“EFFECTIVE DATE”) and any subsequent amendments including an Amendment No. 1 effective as of January 23, 2006, between HOSPITAL and JUNIPER, and an Amendment No. 2 effective as of May 17, 2010, between HOSPITAL and COMPANY (collectively the “ORIGINAL AGREEMENT”).
OPTION for an EXCLUSIVE LICENSE AGREEMENT*Exclusive License Agreement • February 20th, 2024 • California
This option to negotiate an exclusive license agreement ("OPTION AGREEMENT") is entered into as of the date that this OPTION AGREEMENT is fully executed by both parties ("EFFECTIVE DATE"), and is by and between the Regents of the University of California, a California public corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 acting through its Office of Technology Licensing, at the University of California, Berkeley, having its administrative office at 2150 Shattuck Avenue, Suite 408, Berkeley, CA 94704-1362 (“REGENTS”), and Company Name ("OPTIONEE"), a [State] corporation, having a principal place of business at Company Address.
EXCLUSIVE LICENSE AGREEMENT FOR GCASE by and between AMGEN INC. and RBNC Therapeutics, Inc. Dated as of September 10, 2021Exclusive License Agreement • August 25th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This EXCLUSIVE LICENSE AGREEMENT FOR GCASE (this “Agreement”) is entered into as of September 10, 2021 (the “Execution Date”) by and between AMGEN INC. (“AMGEN”), and RBNC Therapeutics, Inc. (“RBNC”). RBNC and AMGEN are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025 -Exclusive License Agreement • January 8th, 2024
Bothell, WA, San Diego, CA and New York, NY – January 8, 2024 – Immunome, Inc. (Nasdaq: IMNM) and Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), today announced that they have entered into an exclusive, worldwide license agreement under which Immunome has licensed from Zentalis ZPC-21, a preclinical ROR1 antibody-drug conjugate (ADC) with best-in-class potential on track for IND submission in 1Q 2025, and Zentalis’ proprietary ADC platform technology.
EXCLUSIVE LICENSE AGREEMENT BETWEEN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AND FIBROCELL SCIENCE, INC FOR UCLA CASE NO. 2014-142:Exclusive License Agreement • October 7th, 2014 • Fibrocell Science, Inc. • Pharmaceutical preparations • California
THIS EXCLUSIVE LICENSE AGREEMENT AND THE ATTACHED APPENDICES A, B, AND C (collectively, the “Agreement”) is made and is effective this 1st day of June, (the “Effective Date”), by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (“The Regents”), a California corporation having its corporate offices located at 1111 Franklin Street, Oakland, California 94607-5200, acting through The Office of Intellectual Property and Industry Sponsored Research of the University of California, Los Angeles, located at 11000 Kinross Avenue, Suite 200, Los Angeles, CA, 90095-1406, and FIBROCELL SCIENCE, INC. (“Licensee”), a Delaware corporation having a principal place of business at 405 Eagleview Blvd., Exton, PA, 19341.This Agreement refers to The Regents and Licensee collectively as the “Parties” and individually as a “Party.”
